UPR
+0.0 · +0.00%
GBX · LSE

Uniphar Group PLC(UPR) Stock Analysis | Healthcare

GBX --+0.00%
Reward53Moderate
Risk55Medium-High
75%Data
Thin 2% profit margin · Revenue growing 13% YoY
Balanced
Market Cap:946.29M
ⓘ
Reward Rating
53
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
55
Medium-High
Risk Assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on UPR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Uniphar Group PLC?

Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally.

AI Brief Pro

The brief on Uniphar Group PLC

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Uniphar Group PLC?

Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 946.29M, and a P/E ratio of 20.9x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (53)
Company Information
IndustryMedical Distribution
Market Cap946.29M
P/E Ratio20.8824
Beta1.101
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.